Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2011-2-8
pubmed:abstractText
tacrolimus and everolimus are immunosuppressive drugs metabolized by enzymes of the CYP3A subfamily. A common variant of the CYP3A5 gene, CYP3A5*3, results in strongly decreased CYP3A5 activity and has been shown to influence Tacrolimus blood concentrations, but its role for the pharmacogenetics of Everolimus remains unclear. Aim of the study was to examine the role of CYP3A5*3 variant in tacrolimus and everolimus dose and drug levels after heart transplantation.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1399-0012
pubmed:author
pubmed:copyrightInfo
© 2009 John Wiley & Sons A/S.
pubmed:issnType
Electronic
pubmed:volume
25
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
146-50
pubmed:meshHeading
pubmed:articleTitle
The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation.
pubmed:affiliation
Department of Surgery, Division of Transplantation, Medical University Graz, Graz, Austria. daniela.kniepeiss@meduni-graz.at
pubmed:publicationType
Journal Article